These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 22775565)
1. Impaired function of gamma-delta lymphocytes in melanoma patients. Petrini I; Pacini S; Galimberti S; Taddei MR; Romanini A; Petrini M Eur J Clin Invest; 2011 Nov; 41(11):1186-94. PubMed ID: 22775565 [TBL] [Abstract][Full Text] [Related]
2. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349 [TBL] [Abstract][Full Text] [Related]
3. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Petrini I; Pacini S; Petrini M; Fazzi R; Trombi L; Galimberti S Eur J Clin Invest; 2009 Sep; 39(9):813-8. PubMed ID: 19522834 [TBL] [Abstract][Full Text] [Related]
5. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296 [TBL] [Abstract][Full Text] [Related]
6. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685 [TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399 [TBL] [Abstract][Full Text] [Related]
8. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661 [TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075 [TBL] [Abstract][Full Text] [Related]
10. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses. Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630 [TBL] [Abstract][Full Text] [Related]
11. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120 [TBL] [Abstract][Full Text] [Related]
12. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365 [TBL] [Abstract][Full Text] [Related]
13. Persistent ex vivo low number and functional in vitro recovery of circulating gammadelta T cells after removal of a cutaneous primary melanoma. Provinciali M; Re F; Tucci MG; Ricotti F; Lattanzio F Scand J Immunol; 2010 Aug; 72(2):142-9. PubMed ID: 20618773 [TBL] [Abstract][Full Text] [Related]
14. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555 [TBL] [Abstract][Full Text] [Related]
15. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate]. Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589 [TBL] [Abstract][Full Text] [Related]
16. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain. Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461 [TBL] [Abstract][Full Text] [Related]
17. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354 [TBL] [Abstract][Full Text] [Related]
18. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. Takahara M; Miyai M; Tomiyama M; Mutou M; Nicol AJ; Nieda M J Leukoc Biol; 2008 Mar; 83(3):742-54. PubMed ID: 18156189 [TBL] [Abstract][Full Text] [Related]
19. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Poonia B; Pauza CD Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653 [TBL] [Abstract][Full Text] [Related]
20. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]